Table 4. Significance of TGF-β1 and TGF-β2 expression changes in different HCC sample cohorts.
| TGF-β1 | N°HCC Patients | adj. p-value | Mean Log2 (Fold Change) |
|---|---|---|---|
| GSE1898 | 91 | 2,53651E–07 | 0,47 |
| GSE5975 EpCAM negative | 142 | 0,00090135 | −0,34 |
| GSE5975 EpCAM positive | 94 | (0,36864697) | −0,08 |
| iCOD | 140 | NA | −0,72 |
| GSE50579 | 40 | 0,008 | 1,13 |
| GSE4024/GSE1898 | 142 | 0,05 | 0,67 |
| GSE14520 | 247 | (0,35) | 0,04 |
| TGF-β2 | N°HCC Patients | adj. p-value | Mean Log2 (Fold Change) |
|---|---|---|---|
| GSE1898 | 91 | 1,01742E–07 | 0,25 |
| GSE5975 EpCAM negative | 142 | 6,0118E–21 | −0,57 |
| GSE5975 EpCAM positive | 94 | 2,25993E-09 | −0,36 |
| iCOD | 140 | NA | 0,74 |
| GSE50579 | 40 | 0,0001 | 1,42 |
| GSE4024/GSE1898 | 142 | (0,83) | −0,03 |
| GSE14520 | 247 | (0,36) | 0,01 |
Number of patients, p-values and fold change of TGF-β1 and TGF-β2 expression in the respective patient cohorts are listed. Only those cohorts with significant p-values were used for further analysis (See Figure 7). Non-significant p-values are given in brackets. NA = Not announced.